ProMIS Neurosciences, Inc. (NASDAQ:PMN) Insider Neil Cashman Acquires 15,000 Shares

ProMIS Neurosciences, Inc. (NASDAQ:PMN) insider Neil Cashman purchased 15,000 shares of the business’s stock in a transaction on Monday, February 10th. The stock was acquired at an average price of $0.97 per share, with a total value of $14,550.00. Following the purchase, the insider now directly owns 16,617 shares in the company, valued at $16,118.49. This represents a 927.64 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

ProMIS Neurosciences Stock Performance

Shares of PMN stock opened at $0.91 on Thursday. ProMIS Neurosciences, Inc. has a 52-week low of $0.87 and a 52-week high of $2.61. The firm has a market capitalization of $29.85 million, a PE ratio of -9.13 and a beta of 0.56. The stock has a fifty day simple moving average of $0.94 and a two-hundred day simple moving average of $1.08.

Institutional Investors Weigh In On ProMIS Neurosciences

Institutional investors have recently bought and sold shares of the business. Ally Bridge Group NY LLC increased its stake in ProMIS Neurosciences by 50.3% in the 3rd quarter. Ally Bridge Group NY LLC now owns 1,592,605 shares of the company’s stock worth $1,991,000 after buying an additional 533,023 shares in the last quarter. Sphera Funds Management LTD. boosted its holdings in shares of ProMIS Neurosciences by 6.3% during the 3rd quarter. Sphera Funds Management LTD. now owns 1,929,297 shares of the company’s stock valued at $2,412,000 after purchasing an additional 115,084 shares during the last quarter. Finally, Great Point Partners LLC bought a new position in shares of ProMIS Neurosciences during the 3rd quarter valued at about $3,488,000. Hedge funds and other institutional investors own 50.13% of the company’s stock.

ProMIS Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.